ClinicalTrials.gg

Program

Hpk1 Inhibitor PRJ1-3024

Its studies are mostly in Melanoma, led by Zhuhai Yufan Biotechnologies.

Furthest: phase 2, since Mar 29, 20223 company-led studies, 3 open or runningNext primary completion: May 15, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Zhuhai Yufan Biotechnologies33 open or runningphase 2since Mar 29, 2022Dec 7, 2021May 15, 2027phase 2 · NCT05315167

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 7, 2021First study: phase 1 study in Hereditary Sensory and Autonomic NeuropathiesFirst studyNCT05159700 · 39 enrolled · United States
  2. Mar 29, 2022Phase 2 study in Hereditary Sensory and Autonomic NeuropathiesNCT05315167 · 267 planned · China
  3. Dec 4, 2024Phase 2 study in MelanomaNCT06727630 · 40 planned · China

Ahead

  1. May 15, 2027Primary completion: phase 2 study in Hereditary Sensory and Autonomic NeuropathiesNCT05315167

TargetBeta

MAP4K1 →read by rule
“An orally bioavailable inhibitor of the serine/threonine enzyme hematopoietic progenitor kinase-1 (Hpk1; Hpk-1; mitogen-activated protein kinase kinase kinase kinase 1; MAP4K1; MEKKK1), ”NCIt, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06727630Melanoma · China2RecruitingApr 30, 202540
NCT05315167Hereditary Sensory and Autonomic Neuropathies · China2RecruitingMay 15, 2027267
NCT05159700Hereditary Sensory and Autonomic Neuropathies · United States1Active, not recruitingJul 17, 202439

How it is read

Names in the registry

  • “PRJ1-3024”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.